

Scoggins Christopher J  
 Form 3  
 April 03, 2019

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name <b>and</b> Ticker or Trading Symbol	
Â Scoggins Christopher J		(Month/Day/Year)	ABBOTT LABORATORIES [ABT]	
(Last)	(First)	(Middle)	04/01/2019	
100 ABBOTT PARK ROAD			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
ABBOTT PARK,Â ILÂ 60064			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner	6. Individual or Joint/Group Filing(Check Applicable Line)
(City)	(State)	(Zip)	<input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other	<input checked="" type="checkbox"/> Form filed by One Reporting Person
			(give title below) (specify below)	<input type="checkbox"/> Form filed by More than One Reporting Person
			Senior Vice President	

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares without par value	25,300	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Title	Amount or Number of		

Edgar Filing: Scoggins Christopher J - Form 3

				Shares		(I) (Instr. 5)	
Option (right to buy) <sup>(1)</sup>	06/15/2016	06/14/2025	Common shares	47,226	\$ 48.04	D	Â
Option (right to buy) <sup>(2)</sup>	02/19/2017	02/18/2026	Common shares	15,000	\$ 38.4	D	Â
Option (right to buy) <sup>(3)</sup>	02/17/2018	02/16/2027	Common shares	22,196	\$ 44.4	D	Â
Option (right to buy) <sup>(4)</sup>	02/16/2019	02/15/2028	Common shares	64,449	\$ 59.94	D	Â
Option (right to buy) <sup>(5)</sup>	02/22/2020	02/21/2029	Common shares	51,557	\$ 75.9	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Scoggins Christopher J 100 ABBOTT PARK ROAD ABBOTT PARK, IL 60064	Â	Â	Â Senior Vice President	Â

## Signatures

Jessica H. Paik, by power of attorney for Christopher J. Scoggins 04/03/2019

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 15,742 on June 15, 2016, 15,742 on June 15, 2017, and 15,742 on June 15, 2018.

(2) Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments and became fully exercisable on February 19, 2019.

(3) Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of which 7,399 and 7,398 became exercisable on February 17, 2018 and February 17, 2019, respectively, and 7,399 becomes exercisable on February 17, 2020.

(4) Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of which 21,483 became exercisable on February 16, 2019 and 21,483 and 21,483 becomes exercisable on February 16, 2020 and February 16, 2021, respectively.

(5) Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 17,185 on February 22, 2020, 17,186 on February 22, 2021, and 17,186 on February 22, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.